KZA — Kazia Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- AU$18.24m
- AU$14.80m
- AU$0.02m
Brief: Kazia Announces Voluntary Delisting From ASX
Australia's Kazia Therapeutics slumps to 1-yr low on delisting announcement
Brief: Kazia Therapeutics Announces Intention To Voluntarily De-List From ASX
Brief: Kazia Therapeutics Seeks Trading Halt
Brief: Kazia Therapeutics Posts Loss For Year Attributable A$20.5 Mln
Brief: Kazia Therapeutics Says Resignation Of Iain Ross As Chairman
Brief: Kazia Therapeutics Says Paxalisib Awarded Fast Track Designation By United States FDA
Brief: Kazia's Paxalisib Receives Fast Track Designation From FDA For Treatment Of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations In Combination With Radiation Therapy
Brief: Kazia Therapeutics Says CEO And Managing Director James Garner Has Resigned
Brief: Kazia Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Kazia Therapeutics Receives Notification From Listing Qualifications Staff Of Nasdaq
Brief: Kazia Therapeutics Enters Collaboration With Australian And NZ Children's Haematology/Oncology Group
Brief: Kazia Therapeutics Posts HY Loss After Income Tax Benefit Attributable A$13.6 Million
Brief: Kazia Therapeutics Updates On Proceeds Of Capital Raise And Share Purchase Plan
Brief: Kazia Therapeutics Announces Placement Of A$4.5 Mln
Australia's Kazia Therapeutics slumps after discounted capital raise
Brief: Kazia Therapeutics Seeks Trading Halt
Brief: Kazia Launches Preclinical Collaboration With Qimr Berghofer Medical Research Institute And Announces Patent Filing
Brief: Kazia's Paxalisib Demonstrates Positive Monotherapy Efficacy Signals In Preclinical Models Of Melanoma